ACCL: Adversarial constrained-CNN loss for weakly supervised medical image segmentation
This addresses the problem of reducing annotation burden for medical image segmentation, though it is incremental as it builds on constrained-CNN loss methods.
The paper tackles weakly supervised medical image segmentation by proposing a new adversarial constrained-CNN loss paradigm, achieving an average Dice score of 75.4% with only 0.65% annotation ratio, which surpasses prior methods by 11.4%.
We propose adversarial constrained-CNN loss, a new paradigm of constrained-CNN loss methods, for weakly supervised medical image segmentation. In the new paradigm, prior knowledge is encoded and depicted by reference masks, and is further employed to impose constraints on segmentation outputs through adversarial learning with reference masks. Unlike pseudo label methods for weakly supervised segmentation, such reference masks are used to train a discriminator rather than a segmentation network, and thus are not required to be paired with specific images. Our new paradigm not only greatly facilitates imposing prior knowledge on network's outputs, but also provides stronger and higher-order constraints, i.e., distribution approximation, through adversarial learning. Extensive experiments involving different medical modalities, different anatomical structures, different topologies of the object of interest, different levels of prior knowledge and weakly supervised annotations with different annotation ratios is conducted to evaluate our ACCL method. Consistently superior segmentation results over the size constrained-CNN loss method have been achieved, some of which are close to the results of full supervision, thus fully verifying the effectiveness and generalization of our method. Specifically, we report an average Dice score of 75.4% with an average annotation ratio of 0.65%, surpassing the prior art, i.e., the size constrained-CNN loss method, by a large margin of 11.4%. Our codes are made publicly available at https://github.com/PengyiZhang/ACCL.